Document is current
Any future updates will be listed below
-
Authors
Liu, Qianyi
Li, Xinyu
Xu, Hui
Luo, Ying
Cheng, Lin
Liang, Junbin
He, Yuelin
Liu, Haiying
Fang, Jianpei
Huang, Junjiu https://orcid.org/0000-0002-3417-1196
- License Information
-
More Information
Article History
Received: 10 September 2024
Revised: 28 October 2024
Accepted: 25 November 2024
First Online: 2 January 2025
Declarations
:
: The human CD34 + HSPCs were obtained from mobilized peripheral blood of patients with <i>HBB</i> CD41-42 (-TCTT) mutation through apheresis at Sun Yat-sen Memorial Hospital, with approval from the Institutions’ Ethical Committee (No. 2020–328). All patients provided informed consent.All the animal experiments were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (SYSU-IACUC-2020-B079) and followed the legal requirements in China and Guangdong Province.
: Hui Xu, Ying Luo, Lin Cheng, and Junbin Liang are employees of Reforgene Medicine. Author Junjiu Huang is a member of the Editorial Board for Advanced Biotechnology, and the author is not involved in the journal’s review of and decisions related to this manuscript.
